FormsNet3 - Blank Form


 
 
Sequence Number:    

 
 
Date Received: __ __ __ __ - __ __- __ __  

 
 
CIBMTR Center Number    

 
 
CIBMTR Recipient ID:    

 
 
Today's Date: __ __ __ __ - __ __- __ __  

 
 
Date of HSCT for which this form is being completed: __ __ __ __ - __ __- __ __  

 

HSCT type (check all that apply): 

 
  

gfedcb
Autologous

 
 

  
gfedcb

Allogeneic, unrelated

 
 

  
gfedcb

Allogeneic, related

 
 

  
gfedcb

Syngeneic (identical twin)

 

Product type (check all that apply): 

 
  

gfedcb
Marrow

 
 

  
gfedcb

PBSC

 
 

  
gfedcb

Cord blood

 
 

  
gfedcb

Other product

 
 
Specify:    

 
 

Visit:

  
 nmlkji

100 day  
 nmlkji

6 months  
 nmlkji

1 year  
 nmlkji

2 years  
 nmlkji

> 2 years,  

 
 
Specify:    

 
 
1  Specify the date the recipient was evaluated for this report: __ __ __ __ - __ __- __ __  

 
 

2  Did the recipient receive any treatment for systemic sclerosis since the date of the last report?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

3  Antithymocyte globulin (ATG)/antilymphocyte globulin (ALG)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
4  Reason for therapy:   

 
 
5  Specify other reason:    

 
 
6  Date therapy started: __ __ __ __ - __ __- __ __  

 
 

7  Currently Receiving?

    
 nmlkji

yes  
 nmlkji

no  

 
 

8  Cyclophosphamide (CTX, Cytoxan, Neosar)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
9  Reason for therapy:   

 
 
10  Specify other reason:    

 
 
11  Date therapy started: __ __ __ __ - __ __- __ __  

 
 

12  Currently Receiving?

    
 nmlkji

yes  
 nmlkji

no  

  Key Pages 

Disease Assessment Post-HSCT Questions: 1 - 1

  Post-HSCT Treatment for Systemic Sclerosis Questions: 2 - 58

Form 2144 R2.0: Systemic Sclerosis Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2144 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 1 / 9



 
 

13  Cyclosporine (CsA, Neoral, Sandimmune)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
14  Reason for therapy:   

 
 
15  Specify other reason:    

 
 
16  Date therapy started: __ __ __ __ - __ __- __ __  

 
 

17  Currently Receiving?

    
 nmlkji

yes  
 nmlkji

no  

 
 

18  D-penicillamine (penicilamine, Cuprimine, Depen)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
19  Reason for therapy:   

 
 
20  Specify other reason:    

 
 
21  Date therapy started: __ __ __ __ - __ __- __ __  

 
 

22  Currently Receiving?

    
 nmlkji

yes  
 nmlkji

no  

 
 

23  Methotrexate (MTX, Folex)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
24  Reason for therapy:   

 
 
25  Specify other reason:    

 
 
26  Date therapy started: __ __ __ __ - __ __- __ __  

 
 

27  Currently Receiving?

    
 nmlkji

yes  
 nmlkji

no  

 
 

28  Mycophenolate mofetil (MMF, CellCept)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
29  Reason for therapy:   

 
 
30  Specify other reason:    

 
 
31  Date therapy started: __ __ __ __ - __ __- __ __  

 
 

32  Currently Receiving?

    
 nmlkji

yes  
 nmlkji

no  

 
 

33  Phototherapy

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
34  Reason for therapy:   

 
 
35  Specify other reason:    

 
 
36  Date therapy started: __ __ __ __ - __ __- __ __  

 
 

37  Currently Receiving?

    
 nmlkji

yes  
 nmlkji

no  

 
 

38  Prednisone (Intensol, Sterapred) or equivalent

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
39  Reason for therapy:   

 
 
40  Specify other reason:    

 
 
41  Date therapy started: __ __ __ __ - __ __- __ __  

 
 

42  Currently Receiving?

    
 nmlkji

yes  
 nmlkji

no  

Form 2144 R2.0: Systemic Sclerosis Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2144 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 2 / 9



 
 

43  Prostanoids/prostaglandin analogs

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
44  Reason for therapy:   

 
 
45  Specify other reason:    

 
 
46  Date therapy started: __ __ __ __ - __ __- __ __  

 
 

47  Currently Receiving?

    
 nmlkji

yes  
 nmlkji

no  

 
 

48  Tacrolimus (FK 506, Prograf)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
49  Reason for therapy:   

 
 
50  Specify other reason:    

 
 
51  Date therapy started: __ __ __ __ - __ __- __ __  

 
 

52  Currently Receiving?

    
 nmlkji

yes  
 nmlkji

no  

 
 

53  Other treatment

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
54  Specify other treatment:    

 
 
55  Reason for therapy:   

 
 
56  Specify other reason:    

 
 
57  Date therapy started: __ __ __ __ - __ __- __ __  

 
 

58  Currently Receiving?

    
 nmlkji

yes  
 nmlkji

no  

 
 
59  Date of evaluation for this reporting period: __ __ __ __ - __ __- __ __  

 
 

60  What was the extent of cutaneous systemic sclerosis at the time of evaluation for this report?

    
 nmlkji

limited (cutaneous thickening distal (but not proximal) to elbows or knees)  

 nmlkji
diffuse  

 nmlkji
Unknown  

 

Specify skin thickness for the following sites as determined by clinical palpation performed at the time of evaluation for this report: Clements P, Lachenbruch P, Seibold J, 

White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22:1281-

1285. 

Indicate Modified Rodnan Skin Thickness Score (MRSS) for each anatomic area below: 

 
61  Face

    
 nmlkji

score 0   - Normal 

 nmlkji
score 1   - Mild 

 nmlkji
score 2   - Moderate 

 nmlkji
score 3   - Severe (inability to pinch skin into a fold) 

  Disease Status at the Time of Evaluation for This Reporting Period Questions: 59 - 91

Form 2144 R2.0: Systemic Sclerosis Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2144 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 3 / 9



 
 

62  Anterior chest

    
 nmlkji

score 0   - Normal 

 nmlkji
score 1   - Mild 

 nmlkji
score 2   - Moderate 

 nmlkji
score 3   - Severe (inability to pinch skin into a fold) 

 
 

63  Abdomen

    
 nmlkji

score 0   - Normal 

 nmlkji
score 1   - Mild 

 nmlkji
score 2   - Moderate 

 nmlkji
score 3   - Severe (inability to pinch skin into a fold) 

 
 

64  Upper arm-left

    
 nmlkji

score 0   - Normal 

 nmlkji
score 1   - Mild 

 nmlkji
score 2   - Moderate 

 nmlkji
score 3   - Severe (inability to pinch skin into a fold) 

 
 

65  Upper arm-right

    
 nmlkji

score 0   - Normal 

 nmlkji
score 1   - Mild 

 nmlkji
score 2   - Moderate 

 nmlkji
score 3   - Severe (inability to pinch skin into a fold) 

 
 

66  Forearm-left

    
 nmlkji

score 0   - Normal 

 nmlkji
score 1   - Mild 

 nmlkji
score 2   - Moderate 

 nmlkji
score 3   - Severe (inability to pinch skin into a fold) 

 
 

67  Forearm-right

    
 nmlkji

score 0   - Normal 

 nmlkji
score 1   - Mild 

 nmlkji
score 2   - Moderate 

 nmlkji
score 3   - Severe (inability to pinch skin into a fold) 

 
 

68  Dorsum of hand-left

    
 nmlkji

score 0   - Normal 

 nmlkji
score 1   - Mild 

 nmlkji
score 2   - Moderate 

 nmlkji
score 3   - Severe (inability to pinch skin into a fold) 

Form 2144 R2.0: Systemic Sclerosis Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2144 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 4 / 9



 
 

69  Dorsum of hand-right

    
 nmlkji

score 0   - Normal 

 nmlkji
score 1   - Mild 

 nmlkji
score 2   - Moderate 

 nmlkji
score 3   - Severe (inability to pinch skin into a fold) 

 
 

70  Fingers-left

    
 nmlkji

score 0   - Normal 

 nmlkji
score 1   - Mild 

 nmlkji
score 2   - Moderate 

 nmlkji
score 3   - Severe (inability to pinch skin into a fold) 

 
 

71  Fingers-right

    
 nmlkji

score 0   - Normal 

 nmlkji
score 1   - Mild 

 nmlkji
score 2   - Moderate 

 nmlkji
score 3   - Severe (inability to pinch skin into a fold) 

 
 

72  Thigh-left

    
 nmlkji

score 0   - Normal 

 nmlkji
score 1   - Mild 

 nmlkji
score 2   - Moderate 

 nmlkji
score 3   - Severe (inability to pinch skin into a fold) 

 
 

73  Thigh-right

    
 nmlkji

score 0   - Normal 

 nmlkji
score 1   - Mild 

 nmlkji
score 2   - Moderate 

 nmlkji
score 3   - Severe (inability to pinch skin into a fold) 

 
 

74  Lower leg-left

    
 nmlkji

score 0   - Normal 

 nmlkji
score 1   - Mild 

 nmlkji
score 2   - Moderate 

 nmlkji
score 3   - Severe (inability to pinch skin into a fold) 

 
 

75  Lower leg-right

    
 nmlkji

score 0   - Normal 

 nmlkji
score 1   - Mild 

 nmlkji
score 2   - Moderate 

 nmlkji
score 3   - Severe (inability to pinch skin into a fold) 

Form 2144 R2.0: Systemic Sclerosis Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2144 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 5 / 9



 
 

76  Dorsum of foot-left

    
 nmlkji

score 0   - Normal 

 nmlkji
score 1   - Mild 

 nmlkji
score 2   - Moderate 

 nmlkji
score 3   - Severe (inability to pinch skin into a fold) 

 
 

77  Dorsum of foot-right

    
 nmlkji

score 0   - Normal 

 nmlkji
score 1   - Mild 

 nmlkji
score 2   - Moderate 

 nmlkji
score 3   - Severe (inability to pinch skin into a fold) 

 
 
78  Total modified Rodnan Skin Score:(add scores from questions 61-77)    

 

Specify the following clinical findings at the time of evaluation for this report:  

 
79  Changes in skin pigmentation:

    
 nmlkji

Present  
 nmlkji

Absent  
 nmlkji

Unknown  

 
 

80  Raynaud's phenomenon:

    
 nmlkji

Present  
 nmlkji

Absent  
 nmlkji

Unknown  

 
 

81  Painful digital ulcers:

    
 nmlkji

Present  
 nmlkji

Absent  
 nmlkji

Unknown  

 
 
82  Specify number of digital ulcers    

 
 

83  Gut dysmotility:

    
 nmlkji

Present  
 nmlkji

Absent  
 nmlkji

Unknown  

 
 

84  Malabsorption:

    
 nmlkji

Present  
 nmlkji

Absent  
 nmlkji

Unknown  

 
 

85  Weight loss > 10% of body weight:

    
 nmlkji

Present  
 nmlkji

Absent  
 nmlkji

Unknown  

 
 

86  Muscle weakness

    
 nmlkji

Present  
 nmlkji

Absent  
 nmlkji

Unknown  

 
 

87  Joint tenderness:

    
 nmlkji

Present  
 nmlkji

Absent  
 nmlkji

Unknown  

 
 
88  Specify number of joints affected:    

 
 

89  Tendon friction rubs:

    
 nmlkji

Present  
 nmlkji

Absent  
 nmlkji

Unknown  

 
 
90  Specify number of sites affected:    

 
 

91  Contractures:

    
 nmlkji

Present  
 nmlkji

Absent  
 nmlkji

Unknown  

 
 

92  Serum creatinine

    
 nmlkji

Known  
 nmlkji

Not known  

  Laboratory Studies at the Time of Evaluation for This Reporting Period Questions: 92 - 140

Form 2144 R2.0: Systemic Sclerosis Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2144 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 6 / 9



  
 
93  .    

 

 nmlkji
mg/dL  

 nmlkji
mmol/L  

 nmlkji
µmol/L  

 
 

94  Creatinine clearance:

    
 nmlkji

Known  
 nmlkji

Not known  

  
 
95  .    

 

 nmlkji
mL/min  

 nmlkji
mL/sec  

 
 

96  Creatinine phosphokinase:

    
 nmlkji

Known  
 nmlkji

Not known  

  
 
97  .    

 

 nmlkji
U/L  

 nmlkji
µkat/L  

 
 

98  Blood urea nitrogen

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
99  .    

 

 nmlkji
mg/dL  

 nmlkji
mmol/L  

 
 

100  Was there evidence of hematuria at the time of evaluation for this report?

    
 nmlkji

yes, present  
 nmlkji

no, absent  
 nmlkji

Unknown  

 
 

101  Was there evidence of proteinuria at the time of evaluation for this report?

    
 nmlkji

yes, present  
 nmlkji

no, absent  
 nmlkji

Unknown  

 
 

102  Thyroid stimulating hormone (TSH):

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
103  .    

 

 nmlkji
mU/L  

 nmlkji
μU/ml  

 
 

104  Was any testing for autoantibodies performed since the date of the last report?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify the test results for the following autoantibodies: 
 

105  Anti-centromere:

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Inconclusive  
 nmlkji

not tested / unknown  

 
 

106  Anti-DNA topoi- 
somerase I (ScI-70):

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Inconclusive  
 nmlkji

not tested / unknown  

 
 

107  Anti-nuclear:

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Inconclusive  
 nmlkji

not tested / unknown  

 
 

108  Anti-SS-A:

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Inconclusive  
 nmlkji

not tested / unknown  

 
 

109  Anti-SS-B:

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Inconclusive  
 nmlkji

not tested / unknown  

 

Specify the results of the following pulmonary function tests performed since the date of the last report:  
 

110  Was dyspnea present on exertion?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

111  Vital capacity (VC):

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
112  .    % (predicted value) 

Form 2144 R2.0: Systemic Sclerosis Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2144 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 7 / 9



 
 

113  Was the actual VC value in the normal range
(≥ 80% of predicted value)? 

    
 nmlkji

yes  
 nmlkji

no  

 
 

114  DLCO:
    

 nmlkji
Known  

 nmlkji
Not known  

 
 
115  .    % (predicted value) 

 
 

116  Was the actual DLCO value in the normal
range (≥ 80% of predicted value)? 

    
 nmlkji

yes  
 nmlkji

no  

 
 

117  DLCO corrected for hemoglobin:
    

 nmlkji
Known  

 nmlkji
Unknown  

 
 
118  .    % (predicted value) 

 
 

119  Was the DLCO value (corrected for hemoglobin)
in the normal range (≥ 80% of predicted value)?

    
 nmlkji

yes  
 nmlkji

no  

 
 

120  Was oxygen desaturation present on exercise testing?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

121  Was ground glass appearance present on chest x-ray?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

122  Was a high resolution chest CT scan performed?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

123  Was ground glass appearance present on CT scan?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

124  Was pulmonary artery hypertension present?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

125  Specify the mean pulmonary artery pressure (PAP) level:

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
126  .    mm/Hg 

 
 

127  Specify the method used to examine the PAP level:

    
 nmlkji

echocardiogram  
 nmlkji

catheterization  

 
 

128  Was systemic hypertension present that required treatment?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify treatment(s) given for hypertension: 
 

129  ACE inhibitor

    
 nmlkji

yes  
 nmlkji

no  

 
 

130  Other antihypertensive therapy

    
 nmlkji

yes  
 nmlkji

no  

 
 
131  Specify antihypertensive therapy:    

 
 
132  Specify the duration of antihypertensive therapy:    

 
 

133  Was arrythmia present that required treatment?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

Form 2144 R2.0: Systemic Sclerosis Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2144 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 8 / 9



 
 

134  Was an echocardiogram performed at the time of evaluation for this report?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

135  Was pericardial effusion present?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

136  Specify the size of the area of accumulated excess fluid:

    
 nmlkji

small  
 nmlkji

moderate  
 nmlkji

large  

 
 

137  Specify the left ventricular ejection fraction:

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
138  .    % 

 
 

139  Was a multiple gate acquisition scan (MUGA test/nuclear ventriculography) performed at the time of evaluation for this report?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
140  Specify the left ventricular ejection fraction:    % 

 
141  Did the recipient complete a modified Health Assessment Questionnaire (HAQ) for Scleroderma at the time of evaluation for this report?

    
Steen VD, Medsger Jr. TA. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients 

over time. Arthritis Rheum 1997; 40 (11): 1984–1991. 

 nmlkji
yes  

 nmlkji
no  

 nmlkji
Unknown  

 
 
142  Recipient's score:    

 
 
143  Worst possible score:    

 
 
144  Best possible score:    

  
 
First Name:    

 
Last Name:    

  
 
Phone number:    

 
Fax number:    

 
 
E-mail address:    

  Functional Assessment at the Time of Evaluation for This Report Questions: 141 - 144

Form 2144 R2.0: Systemic Sclerosis Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2144 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 9 / 9